vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$22.38 USD
+1.03 (4.83%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $22.97 +0.59 (2.64%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VTVT 22.38 +1.03(4.83%)
Will VTVT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VTVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTVT
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
VTVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VTVT
VTVT forms Pocket Pivot on September 19
VTVT's price rises by 1.52% on September 19, though its technical setup remains stable.
Is VTVT building bullish momentum? Slingshot Bullish shows up after sliding 0.69%
vTv Therapeutics trading resumes
vTv Therapeutics trading resumes